IMA402 (bispecific T cell engaging receptor molecule)

Gynecological tumors / Breast cancer, Skin tumors, Thoracic tumors
Endometrial cancer, Melanoma, Non-small cell lung cancer (NSCLC)
other systemic therapies
The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I) To characterize the safety and tolerability of IMA402 (Phase I/II) To evaluate anti-tumor activity of IMA402 (Phase II) Secondary objectives: To evaluate the initial anti-tumor activity of IMA402 (Phase I) To evaluate anti-tumor activity of IMA402 (Phase II) To describe the PK of IMA402 (Phase I/II)
The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I) To characterize the safety and tolerability of IMA402 (Phase I/II) To evaluate anti-tumor activity of IMA402 (Phase II) Secondary objectives: To evaluate the initial anti-tumor activity of IMA402 (Phase I) To evaluate anti-tumor activity of IMA402 (Phase II) To describe the PK of IMA402 (Phase I/II)